Vol 1, No 4 (2010)
Case report
Published online: 2010-11-24

open access

Page views 806
Article views/downloads 4978
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy of bendamustine combined with rituximab in the treatment of relapsed chronic lymphocytic leukemia

Wioletta Kamińska, Maria Luiza Kusz, Iwona Hus
Hematologia 2010;1(4):359-363.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia diagnosed in adults in Western Europe and Northern America. Despite the progress in CLL therapy it still remains incurable. CLL is primarily a disease of the elderly, most patients are aged over 65 years and have at least 2 co-morbidities. A large proportion of patients are therefore not suitable for intensive chemotherapy. In treating older patients with CLL, not only treatment benefits but also toxicities need to be taken into account. Phase II study results showed that bendamustine plus rituximab (BR) was safe and effective in the treatment of refractory/relapsed CLL. We present a patient with relapsed disease, with infectious complications after previous purine analogues, and who achieved a complete remision after therapy with BR protocol.
Hematologia 2010; 1, 4: 359-363

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice